137 related articles for article (PubMed ID: 7403251)
21. Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age.
Patamasucon P; Kaojarern S; Kusmiesz H; Nelson JD
Antimicrob Agents Chemother; 1981 May; 19(5):736-9. PubMed ID: 6975059
[TBL] [Abstract][Full Text] [Related]
22. Jaundice due to erythromycin estolate.
Lunzer MR; Huang SN; Ward KM; Sherlock S
Gastroenterology; 1975 May; 68(5 Pt 1):1284-91. PubMed ID: 1126604
[TBL] [Abstract][Full Text] [Related]
23. Erythromycin estolate-induced hepatitis. Ultrastructural study of liver.
Gafter U; Mandel EM; Weiss S; Djaldetti M
N Y State J Med; 1979 Jan; 79(1):87-9. PubMed ID: 282477
[No Abstract] [Full Text] [Related]
24. Hepatotoxicity of erythromycin estolate during pregnancy.
McCormack WM; George H; Donner A; Kodgis LF; Alpert S; Lowe EW; Kass EH
Antimicrob Agents Chemother; 1977 Nov; 12(5):630-5. PubMed ID: 21610
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography.
Croteau D; Bergeron MG; LeBel M
Antimicrob Agents Chemother; 1988 Apr; 32(4):561-5. PubMed ID: 3259856
[TBL] [Abstract][Full Text] [Related]
26. Comparison of erythromycin base and estolate in gonococcal urethritis.
Brown ST; Pedersen HB; Holmes KK
JAMA; 1977 Sep; 238(13):1371-3. PubMed ID: 408522
[TBL] [Abstract][Full Text] [Related]
27. Concentrations of erythromycin in serum and tonsil: comparison of the estolate and ethyl succinate suspensions.
Ginsburg CM; McCracken GH; Culbertson MC
J Pediatr; 1976 Dec; 89(6):1011-3. PubMed ID: 792404
[TBL] [Abstract][Full Text] [Related]
28. Comparative liver toxicity of various erythromycin derivatives in animals.
Viluksela M; Hanhijärvi H; Husband RF; Kosma VM; Collan Y; Männistö PT
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():9-27. PubMed ID: 3391880
[TBL] [Abstract][Full Text] [Related]
29. Erythromycin jaundice: diagnosis by an in vitro challenge test.
Cooksley WG; Powell LW
Aust N Z J Med; 1977 Jun; 7(3):291-3. PubMed ID: 269690
[TBL] [Abstract][Full Text] [Related]
30. Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity.
Pari L; Murugan P
Pharmacol Res; 2004 May; 49(5):481-6. PubMed ID: 14998559
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals.
Lakritz J; Wilson WD; Marsh AE; Mihalyi JE
Am J Vet Res; 2000 Aug; 61(8):914-9. PubMed ID: 10951982
[TBL] [Abstract][Full Text] [Related]
32. Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.
Welling PG; Elliott RL; Pitterle ME; Corrick-West HP; Lyons LL
J Pharm Sci; 1979 Feb; 68(2):150-5. PubMed ID: 423080
[TBL] [Abstract][Full Text] [Related]
33. Erythromycin estolate hepatotoxicity.
Lloyd-Still JD; Sherman JO; Boggs J; Demers LM
Am J Dis Child; 1978 Mar; 132(3):320. PubMed ID: 629252
[No Abstract] [Full Text] [Related]
34. Erythromycin in the aqueous. Comparative concentrations form the estolate and from the base.
Nolan J; Lyle WH
Trans Ophthalmol Soc U K (1962); 1976 Jul; 96(2):338-40. PubMed ID: 797069
[No Abstract] [Full Text] [Related]
35. Experimental bases for the different hepatotoxicity of erythromycin preparations in man.
Dujovne CA; Shoeman D; Bianchine J; Lasagna L
J Lab Clin Med; 1972 May; 79(5):832-44. PubMed ID: 5018747
[No Abstract] [Full Text] [Related]
36. Effects of in vivo treatment with a new fluorinated macrolide (P-0501A) and other erythromycins on drug clearance and hepatic functions in perfused rat liver.
Villa P; Corti F; Guaitani A; Bartosek I; Casacci F; De Marchi F; Pacei E
J Antibiot (Tokyo); 1986 Jun; 39(6):839-45. PubMed ID: 3733532
[TBL] [Abstract][Full Text] [Related]
37. Variability in the absorption and disposition of erythromycin estolate in humans.
Stubbs C; Kanfer I
J Pharm Sci; 1989 Aug; 78(8):635-8. PubMed ID: 2778669
[TBL] [Abstract][Full Text] [Related]
38. Erythromycin propionate and estolate.
Farre M
Lancet; 1988 Jul; 2(8601):45. PubMed ID: 2898648
[No Abstract] [Full Text] [Related]
39. Risk-benefit equation for erythromycin estolate.
LeBel M
Am J Hosp Pharm; 1980 Feb; 37(2):176, 180. PubMed ID: 7361788
[No Abstract] [Full Text] [Related]
40. Cholestatic jaundice in patients treated with erythromycin estolate.
HAVENS WP
JAMA; 1962 Apr; 180():30-2. PubMed ID: 13905478
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
